Home

BioM AG is a consultancy and investment company that is independent of the cluster management agency BioM GmbH. Its head office is located at Martinsried in the heart of the biotech cluster.

» mehr

All information on the Munich Biotech Region and the Leading-Edge Cluster m4 - Personalized Medicine and Targeted Therapies. Cluster management is handled by BioM GmbH.

» mehr

The network of Bavarian biotech regions comprises all the research institutions and companies operating in the life science sector and is coordinated by BioM GmbH.

» mehr

  • » 23.10.2014 4th Munich Biomarker Conference
    The interdisciplinary programme of the European Networking Event for Personalized Medicine on November 25th-26th, 2014 is now nearly complete. More and more participants now also register to the partnering and submit their profiles. The congress with exhibition and partnering connects researchers and physicians with the biotech and pharma... » more
  • Marlies Sproll, CSO of MorphoSys » 23.10.2014 MorphoSys has now 3 antibodies in phase-3 - with pharma partners
    Roche, Novartis and now Janssen are the 3 big pharma, whose partnering programmes with a specific MOR antibody have already reached the decisive clinical phase 3. » more
  • » 15.10.2014 Made in Munich: Amgen heading for "Bite" approval
    The American biotech giant Amgen has submitted an application to the immunomolecule blinatumomab, a bispecific antibody which was and is developed in Munich. » more
  • » 14.10.2014 NIH/DOD Non-Dilutive Funding Opportunities
    The seminar on December 4th informs about funding opportunities in the US. Currently, the National Institutes of Health (NIH) are actively funding 1,124 projects amounting to $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign... » more
  • » 13.10.2014 IDBS Munich Best Practices R&D Forum
    The forum on November 20th has the undertitle "From endless paper to high productivity". R&D is a highly volatile, dynamic and disparate environment. Often, important data exists across multiple systems making aggregating critical information difficult. From research through development into pilot production and manufacturing,... » more
  • » 01.10.2014 4th Munich Biomarker Conference - early bird discount
    Until October 10th, the 4th Munich Biomarker Conference on November 25th-26th, 2014 offers you an attractive early bird discount on the registration fee.  Have a look at the interdisciplinary programme of the European Networking Event for Personalized Medicine. The congress with exhibition and partnering connects researchers and physicians... » more